Last reviewed · How we verify

INF2.0 + IBU — Competitive Intelligence Brief

INF2.0 + IBU (INF2.0 + IBU) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination therapy (interferon + NSAID). Area: Immunology / Virology.

marketed Combination therapy (interferon + NSAID) Immunology / Virology Small molecule Live · refreshed every 30 min

Target snapshot

INF2.0 + IBU (INF2.0 + IBU) — St. Justine's Hospital. INF2.0 + IBU is a combination of interferon alpha-2b (INF2.0) and ibuprofen (IBU) that combines antiviral/immunomodulatory effects with anti-inflammatory and analgesic properties.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
INF2.0 + IBU TARGET INF2.0 + IBU St. Justine's Hospital marketed Combination therapy (interferon + NSAID)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination therapy (interferon + NSAID) class)

  1. St. Justine's Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). INF2.0 + IBU — Competitive Intelligence Brief. https://druglandscape.com/ci/inf2-0-ibu. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: